News
Burrill & Company Leads $12.9 Million Series E Round In WhiteGlove Health April 16, 2012 | Press Release
Burrill & Company Leads $16.5 Million Round in WaveTec Vision to Commercialize Its Cataract Surgery Breakthrough April 16, 2012 | Press Release
Burrill & Company Leads ADMA Biologics’ $17.5 Million Private Placement April 15, 2012 | Press Release
See all NewsInternational

Chen Yee Liaw
Business AnalystMalaysia
Chen Yee joined Burrill & Company in June of 2011 as Business Analyst, and has been working with the Malaysian Life Sciences Capital Fund (MLSCF) since 2009. She is instrumental in evaluating biotechnology companies in the cleantech sectors, where she helps develop insights and investment strategy for the Malaysian fund through market, technical, competitive and financial analyses. Concurrently, Chen Yee serves as Business Analyst at Abunda Nutrition, a portfolio company of MLSCF. At Abunda, she is actively involved in business and corporate development activities, where she helps to identify potential molecules for pipeline expansion, develop insights to guide manufacturing and commercialization strategies, as well as perform financial modelling. Prior to Burrill and MLSCF, Chen Yee interned at Deloitte Consulting, in Strategy & Operations. She also did research at Caltech, elucidating the molecular basis of early T-cell development defects that may impact autoimmunity in a Type 1 diabetes mouse model. She holds a B.S. (Honors) in Biology and Business Economics from the California Institute of Technology (Caltech), and was recipient of the prestigious Upper Class Merit Award.
